Analyzing Else Nutrn (OTCMKTS:BABYF) & OraSure Technologies (NASDAQ:OSUR)

Else Nutrn (OTCMKTS:BABYF) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Else Nutrn and OraSure Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Else Nutrn	0	0	0	0	0.00
OraSure Technologies	1	2	0	0	1.67

OraSure Technologies has a consensus price target of $3.00, indicating a potential upside of 12.78%. Given OraSure Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe OraSure Technologies is more favorable than Else Nutrn.

Risk & Volatility

Else Nutrn has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Profitability

This table compares Else Nutrn and OraSure Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Else Nutrn	-152.45%	-4,500.62%	-162.11%
OraSure Technologies	-47.92%	-13.61%	-11.68%

Earnings & Valuation

This table compares Else Nutrn and OraSure Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Else Nutrn	$5.82 million	0.53	-$11.08 million	($0.61)	-0.13
OraSure Technologies	$125.70 million	1.52	-$19.50 million	($0.80)	-3.33

Else Nutrn has higher earnings, but lower revenue than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Else Nutrn, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

93.5% of OraSure Technologies shares are owned by institutional investors. 3.9% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

OraSure Technologies beats Else Nutrn on 9 of the 13 factors compared between the two stocks.

About Else Nutrn

Else Nutrition Holdings Inc. focuses on the research, development, manufacturing, marketing, and sale of plant-based food and nutrition products for infants, toddlers, children's, and adults in North America, Israel, Australia, and New Zealand. It offers baby and toddler snacks; baby feeding accessories, such as feeding bottles and teats; plant-based baby and toddler nutrition formula products; kids and adult nutrition products; and complementary food products for babies, as well as toddler drink for toddlers ages 12-36 months; and follow-on formula for infants. The company provides its products through online. Else Nutrition Holdings Inc. was founded in 2012 and is headquartered in Tel Aviv, Israel.

About OraSure Technologies

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.